PCIDB

KNApSAcK Metabolite C00018192

Metabolite

KNApSAcK Entry

id C00018192
Name Ionomycin
CAS RN 56092-81-0
Standard InChI InChI=1S/C41H72O9/c1-25(21-29(5)34(43)24-35(44)30(6)22-27(3)20-26(2)14-15-38(46)47)12-11-13-28(4)39(48)31(7)36(45)23-33-16-18-41(10,49-33)37-17-19-40(9,50-37)32(8)42/h11,13,24-33,36-37,39,42-43,45,48H,12,14-23H2,1-10H3,(H,46,47)/b13-11+,34-24-/t25-,26-,27+,28-,29-,30+,31+,32-,33+,36+,37-,39-,40+,41+/m1/s1
Standard InChI (Main Layer) InChI=1S/C41H72O9/c1-25(21-29(5)34(43)24-35(44)30(6)22-27(3)20-26(2)14-15-38(46)47)12-11-13-28(4)39(48)31(7)36(45)23-33-16-18-41(10,49-33)37-17-19-40(9,50-37)32(8)42/h11,13,24-33,36-37,39,42-43,45,48H,12,14-23H2,1-10H3,(H,46,47)

Cluster

Phytochemical cluster
KCF-S cluster No. 8642

Link

ChEMBL

By standard InChI CHEMBL501617
By standard InChI Main Layer CHEMBL501617

KEGG

By LinkDB

CTD

By CAS RN D015759

Species

Summary

Plant class

class name count

Family

family name count
Streptomycetaceae 1

List (1)

* NCBI
KNApSAcK organism *ID *family *plant class *kingdom
Streptomyces conglobatus sp. nov. 1883 Streptomycetaceae Bacteria

Human Protein / Gene in interaction

4 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P11473 Vitamin D3 receptor NR1I1 CHEMBL501617 CHEMBL1794311 (2)
2 / 3
P00352 Retinal dehydrogenase 1 Enzyme CHEMBL501617 CHEMBL1614458 (1)
0 / 0
Q92830 Histone acetyltransferase KAT2A Enzyme CHEMBL501617 CHEMBL1738606 (1)
0 / 0
P10636 Microtubule-associated protein tau Unclassified protein CHEMBL501617 CHEMBL1614421 (2) CHEMBL1614502 (1)
4 / 3

CTD interaction (327)

compound gene gene name gene description interaction interaction type form reference
pmid
D015759 60 ACTB
BRWS1
PS1TP5BP1
actin, beta [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ACTB mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 60 ACTB
BRWS1
PS1TP5BP1
actin, beta [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ACTB mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 133 ADM
AM
adrenomedullin [Ionomycin co-treated with Lipopolysaccharides] results in decreased expression of ADM protein affects cotreatment
/ decreases expression
protein 20682585
D015759 133 ADM
AM
adrenomedullin Ionomycin results in decreased expression of ADM mRNA decreases expression
mRNA 20682585
D015759 133 ADM
AM
adrenomedullin Ionomycin results in decreased expression of ADM protein decreases expression
protein 20682585
D015759 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) [Ionomycin co-treated with EGF protein] results in increased phosphorylation of AKT1 protein affects cotreatment
/ increases phosphorylation
protein 22317921
D015759 10109 ARPC2
ARC34
PNAS-139
p34-Arc
actin related protein 2/3 complex, subunit 2, 34kDa pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ARPC2 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 10109 ARPC2
ARC34
PNAS-139
p34-Arc
actin related protein 2/3 complex, subunit 2, 34kDa [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ARPC2 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 468 ATF4
CREB-2
CREB2
TAXREB67
TXREB
activating transcription factor 4 [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ATF4 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 468 ATF4
CREB-2
CREB2
TAXREB67
TXREB
activating transcription factor 4 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of ATF4 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 489 ATP2A3
SERCA3
ATPase, Ca++ transporting, ubiquitous (EC:3.6.3.8) [Thapsigargin co-treated with Ionomycin] promotes the reaction [STIM1 protein binds to ATP2A3 protein] affects binding
/ affects cotreatment
/ increases reaction
protein 18439569
D015759 597 BCL2A1
ACC-1
ACC-2
BCL2L5
BFL1
GRS
HBPA1
BCL2-related protein A1 [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 597 BCL2A1
ACC-1
ACC-2
BCL2L5
BFL1
GRS
HBPA1
BCL2-related protein A1 bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA]] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 597 BCL2A1
ACC-1
ACC-2
BCL2L5
BFL1
GRS
HBPA1
BCL2-related protein A1 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 597 BCL2A1
ACC-1
ACC-2
BCL2L5
BFL1
GRS
HBPA1
BCL2-related protein A1 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of BCL2A1 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 796 CALCA
CALC1
CGRP
CGRP-I
CGRP1
CT
KC
calcitonin-related polypeptide alpha [Ionomycin co-treated with Lipopolysaccharides] results in increased expression of CALCA protein affects cotreatment
/ increases expression
protein 20682585
D015759 796 CALCA
CALC1
CGRP
CGRP-I
CGRP1
CT
KC
calcitonin-related polypeptide alpha Ionomycin promotes the reaction [Lipopolysaccharides results in increased expression of CALCA mRNA] increases expression
/ increases reaction
mRNA 20682585
D015759 796 CALCA
CALC1
CGRP
CGRP-I
CGRP1
CT
KC
calcitonin-related polypeptide alpha Ionomycin results in increased expression of CALCA mRNA increases expression
mRNA 20682585
D015759 796 CALCA
CALC1
CGRP
CGRP-I
CGRP1
CT
KC
calcitonin-related polypeptide alpha Verapamil inhibits the reaction [[Ionomycin co-treated with Lipopolysaccharides] results in increased expression of CALCA protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 20682585
D015759 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CASP3 protein affects cotreatment
/ increases activity
protein 12165276
D015759 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA]] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of CASP8 protein affects cotreatment
/ increases activity
protein 12165276
D015759 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 841 CASP8
ALPS2B
CAP4
Casp-8
FLICE
MACH
MCH5
caspase 8, apoptosis-related cysteine peptidase (EC:3.4.22.61) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CASP8 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 6356 CCL11
SCYA11
chemokine (C-C motif) ligand 11 [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL11 protein affects cotreatment
/ increases secretion
protein 17685462
D015759 6356 CCL11
SCYA11
chemokine (C-C motif) ligand 11 sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL11 protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 17685462
D015759 6356 CCL11
SCYA11
chemokine (C-C motif) ligand 11 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL11 protein affects cotreatment
/ increases expression
protein 17572062
D015759 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL2 protein affects cotreatment
/ increases secretion
protein 17685462
D015759 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL2 protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 17685462
D015759 6347 CCL2
GDCF-2
HC11
HSMCR30
MCAF
MCP-1
MCP1
SCYA2
SMC-CF
chemokine (C-C motif) ligand 2 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL2 protein affects cotreatment
/ increases expression
protein 17572062
D015759 6348 CCL3
G0S19-1
LD78ALPHA
MIP-1-alpha
MIP1A
SCYA3
chemokine (C-C motif) ligand 3 [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 6348 CCL3
G0S19-1
LD78ALPHA
MIP-1-alpha
MIP1A
SCYA3
chemokine (C-C motif) ligand 3 [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL3 protein affects cotreatment
/ increases secretion
protein 17685462
D015759 6348 CCL3
G0S19-1
LD78ALPHA
MIP-1-alpha
MIP1A
SCYA3
chemokine (C-C motif) ligand 3 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 6348 CCL3
G0S19-1
LD78ALPHA
MIP-1-alpha
MIP1A
SCYA3
chemokine (C-C motif) ligand 3 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 6348 CCL3
G0S19-1
LD78ALPHA
MIP-1-alpha
MIP1A
SCYA3
chemokine (C-C motif) ligand 3 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3 protein affects cotreatment
/ increases expression
protein 17572062
D015759 6349 CCL3L1
464.2
D17S1718
G0S19-2
LD78
LD78BETA
MIP1AP
SCYA3L
SCYA3L1
chemokine (C-C motif) ligand 3-like 1 [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3L1 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 6349 CCL3L1
464.2
D17S1718
G0S19-2
LD78
LD78BETA
MIP1AP
SCYA3L
SCYA3L1
chemokine (C-C motif) ligand 3-like 1 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL3L1 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 6351 CCL4
ACT2
AT744.1
G-26
HC21
LAG-1
LAG1
MIP-1-beta
MIP1B
MIP1B1
SCYA2
SCYA4
chemokine (C-C motif) ligand 4 [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL4 protein affects cotreatment
/ increases secretion
protein 17685462
D015759 6351 CCL4
ACT2
AT744.1
G-26
HC21
LAG-1
LAG1
MIP-1-beta
MIP1B
MIP1B1
SCYA2
SCYA4
chemokine (C-C motif) ligand 4 sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL4 protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 17685462
D015759 6351 CCL4
ACT2
AT744.1
G-26
HC21
LAG-1
LAG1
MIP-1-beta
MIP1B
MIP1B1
SCYA2
SCYA4
chemokine (C-C motif) ligand 4 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL4 protein affects cotreatment
/ increases expression
protein 17572062
D015759 9560 CCL4L1
AT744.2
CCL4L
LAG-1
LAG1
SCYA4L
chemokine (C-C motif) ligand 4-like 1 [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL4L1 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 9560 CCL4L1
AT744.2
CCL4L
LAG-1
LAG1
SCYA4L
chemokine (C-C motif) ligand 4-like 1 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL4L1 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 6352 CCL5
D17S136E
RANTES
SCYA5
SIS-delta
SISd
TCP228
eoCP
chemokine (C-C motif) ligand 5 [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL5 protein affects cotreatment
/ increases secretion
protein 17685462
D015759 6352 CCL5
D17S136E
RANTES
SCYA5
SIS-delta
SISd
TCP228
eoCP
chemokine (C-C motif) ligand 5 sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CCL5 protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 17685462
D015759 6352 CCL5
D17S136E
RANTES
SCYA5
SIS-delta
SISd
TCP228
eoCP
chemokine (C-C motif) ligand 5 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCL5 protein affects cotreatment
/ increases expression
protein 17572062
D015759 900 CCNG1
CCNG
cyclin G1 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CCNG1 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 900 CCNG1
CCNG
cyclin G1 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CCNG1 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 22948 CCT5
CCT-epsilon
CCTE
TCP-1-epsilon
chaperonin containing TCP1, subunit 5 (epsilon) [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 22948 CCT5
CCT-epsilon
CCTE
TCP-1-epsilon
chaperonin containing TCP1, subunit 5 (epsilon) bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA]] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 22948 CCT5
CCT-epsilon
CCTE
TCP-1-epsilon
chaperonin containing TCP1, subunit 5 (epsilon) pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 22948 CCT5
CCT-epsilon
CCTE
TCP-1-epsilon
chaperonin containing TCP1, subunit 5 (epsilon) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CCT5 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 4345 CD200
MOX1
MOX2
MRC
OX-2
CD200 molecule [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD200 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 4345 CD200
MOX1
MOX2
MRC
OX-2
CD200 molecule pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD200 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 4345 CD200
MOX1
MOX2
MRC
OX-2
CD200 molecule [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD200 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 960 CD44
CDW44
CSPG8
ECMR-III
HCELL
HUTCH-I
IN
LHR
MC56
MDU2
MDU3
MIC4
Pgp1
CD44 molecule (Indian blood group) [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD44 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 960 CD44
CDW44
CSPG8
ECMR-III
HCELL
HUTCH-I
IN
LHR
MC56
MDU2
MDU3
MIC4
Pgp1
CD44 molecule (Indian blood group) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CD44 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 1015 CDH17
CDH16
HPT-1
HPT1
cadherin 17, LI cadherin (liver-intestine) [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CDH17 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 1015 CDH17
CDH16
HPT-1
HPT1
cadherin 17, LI cadherin (liver-intestine) pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CDH17 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 1015 CDH17
CDH16
HPT-1
HPT1
cadherin 17, LI cadherin (liver-intestine) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CDH17 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 1072 CFL1
CFL
cofilin 1 (non-muscle) Egtazic Acid inhibits the reaction [Ionomycin results in decreased phosphorylation of and results in increased activity of CFL1 protein] decreases phosphorylation
/ decreases reaction
/ increases activity
protein 17303079
D015759 1072 CFL1
CFL
cofilin 1 (non-muscle) Ionomycin results in decreased phosphorylation of and results in increased activity of CFL1 protein decreases phosphorylation
/ increases activity
protein 17303079
D015759 1201 CLN3
BTS
JNCL
ceroid-lipofuscinosis, neuronal 3 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CLN3 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 1201 CLN3
BTS
JNCL
ceroid-lipofuscinosis, neuronal 3 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CLN3 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 1291 COL6A1
OPLL
collagen, type VI, alpha 1 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of COL6A1 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 1291 COL6A1
OPLL
collagen, type VI, alpha 1 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of COL6A1 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 1312 COMT
catechol-O-methyltransferase (EC:2.1.1.6) [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of COMT mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 1312 COMT
catechol-O-methyltransferase (EC:2.1.1.6) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of COMT mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 1390 CREM
CREM-2
ICER
hCREM-2
cAMP responsive element modulator [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CREM mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 1390 CREM
CREM-2
ICER
hCREM-2
cAMP responsive element modulator pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CREM mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 1390 CREM
CREM-2
ICER
hCREM-2
cAMP responsive element modulator [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CREM mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 1437 CSF2
GMCSF
colony stimulating factor 2 (granulocyte-macrophage) [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CSF2 protein affects cotreatment
/ increases secretion
protein 17685462
D015759 1437 CSF2
GMCSF
colony stimulating factor 2 (granulocyte-macrophage) sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of CSF2 protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 17685462
D015759 1437 CSF2
GMCSF
colony stimulating factor 2 (granulocyte-macrophage) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of CSF2 protein affects cotreatment
/ increases expression
protein 17572062
D015759 1457 CSNK2A1
CK2A1
CKII
CSNK2A3
casein kinase 2, alpha 1 polypeptide (EC:2.7.11.1) Ionomycin promotes the reaction [EGF protein promotes the reaction [CSNK2A1 protein binds to SLC39A7 protein]] affects binding
/ increases reaction
protein 22317921
D015759 1487 CTBP1
BARS
C-terminal binding protein 1 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CTBP1 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 1487 CTBP1
BARS
C-terminal binding protein 1 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CTBP1 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 8065 CUL5
VACM-1
VACM1
cullin 5 [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CUL5 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 8065 CUL5
VACM-1
VACM1
cullin 5 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CUL5 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 8065 CUL5
VACM-1
VACM1
cullin 5 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of CUL5 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 1806 DPYD
DHP
DHPDHASE
DPD
dihydropyrimidine dehydrogenase (EC:1.3.1.2) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which binds to DPYD promoter] affects binding
/ affects cotreatment
/ increases reaction
promoter 15705907
D015759 1806 DPYD
DHP
DHPDHASE
DPD
dihydropyrimidine dehydrogenase (EC:1.3.1.2) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which results in increased expression of DPYD mRNA] affects binding
/ affects cotreatment
/ increases expression
/ increases reaction
mRNA 15705907
D015759 1806 DPYD
DHP
DHPDHASE
DPD
dihydropyrimidine dehydrogenase (EC:1.3.1.2) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DPYD mRNA affects cotreatment
/ increases expression
mRNA 15705907
D015759 1846 DUSP4
HVH2
MKP-2
MKP2
TYP
dual specificity phosphatase 4 (EC:3.1.3.16 3.1.3.48) bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DUSP4 mRNA]] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 1846 DUSP4
HVH2
MKP-2
MKP2
TYP
dual specificity phosphatase 4 (EC:3.1.3.16 3.1.3.48) pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DUSP4 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 1846 DUSP4
HVH2
MKP-2
MKP2
TYP
dual specificity phosphatase 4 (EC:3.1.3.16 3.1.3.48) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of DUSP4 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 1950 EGF
HOMG4
URG
epidermal growth factor [Ionomycin co-treated with EGF protein] results in increased phosphorylation of AKT1 protein affects cotreatment
/ increases phosphorylation
protein 22317921
D015759 1950 EGF
HOMG4
URG
epidermal growth factor [Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK1 protein affects cotreatment
/ increases phosphorylation
protein 22317921
D015759 1950 EGF
HOMG4
URG
epidermal growth factor [Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK3 protein affects cotreatment
/ increases phosphorylation
protein 22317921
D015759 1950 EGF
HOMG4
URG
epidermal growth factor Ionomycin promotes the reaction [EGF protein promotes the reaction [CSNK2A1 protein binds to SLC39A7 protein]] affects binding
/ increases reaction
protein 22317921
D015759 1958 EGR1
AT225
G0S30
KROX-24
NGFI-A
TIS8
ZIF-268
ZNF225
early growth response 1 [Ionomycin results in increased abundance of Calcium] which results in increased expression of EGR1 protein increases abundance
/ increases expression
protein 12517959
D015759 1959 EGR2
AT591
CMT1D
CMT4E
KROX20
early growth response 2 [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EGR2 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 1959 EGR2
AT591
CMT1D
CMT4E
KROX20
early growth response 2 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EGR2 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 1959 EGR2
AT591
CMT1D
CMT4E
KROX20
early growth response 2 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of EGR2 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) Tamoxifen inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Estradiol] results in decreased expression of FASLG mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 20529085
D015759 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Estradiol] results in decreased expression of FASLG mRNA affects cotreatment
/ decreases expression
mRNA 20529085
D015759 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Estradiol] results in decreased expression of FASLG protein affects cotreatment
/ decreases expression
protein 20529085
D015759 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Testosterone] results in increased expression of FASLG mRNA affects cotreatment
/ increases expression
mRNA 20529085
D015759 356 FASLG
ALPS1B
APT1LG1
APTL
CD178
CD95-L
CD95L
FASL
TNFSF6
Fas ligand (TNF superfamily, member 6) [Tetradecanoylphorbol Acetate co-treated with Ionomycin co-treated with Testosterone] results in increased expression of FASLG protein affects cotreatment
/ increases expression
protein 20529085
D015759 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein]] affects cotreatment
/ decreases reaction
/ increases expression
protein 15477007
D015759 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog Capsaicin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 9580328
D015759 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 15477007
D015759 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which binds to DPYD promoter] affects binding
/ affects cotreatment
/ increases reaction
protein 15705907
D015759 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which results in increased expression of DPYD mRNA] affects binding
/ affects cotreatment
/ increases expression
/ increases reaction
protein 15705907
D015759 2353 FOS
AP-1
C-FOS
p55
FBJ murine osteosarcoma viral oncogene homolog [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOS protein affects cotreatment
/ increases expression
protein 9580328
15477007
D015759 2355 FOSL2
FRA2
FOS-like antigen 2 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOSL2 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 2355 FOSL2
FRA2
FOS-like antigen 2 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of FOSL2 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 2533 FYB
ADAP
PRO0823
SLAP-130
FYN binding protein [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FYB mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 2533 FYB
ADAP
PRO0823
SLAP-130
FYN binding protein pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FYB mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 2533 FYB
ADAP
PRO0823
SLAP-130
FYN binding protein [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of FYB mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 2675 GFRA2
GDNFRB
NRTNR-ALPHA
NTNRA
RETL2
TRNR2
GDNF family receptor alpha 2 [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GFRA2 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 2675 GFRA2
GDNFRB
NRTNR-ALPHA
NTNRA
RETL2
TRNR2
GDNF family receptor alpha 2 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GFRA2 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 2675 GFRA2
GDNFRB
NRTNR-ALPHA
NTNRA
RETL2
TRNR2
GDNF family receptor alpha 2 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GFRA2 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 2688 GH1
GH
GH-N
GHN
IGHD1B
hGH-N
growth hormone 1 Ionomycin results in increased secretion of GH1 protein increases secretion
protein 12471042
D015759 10578 GNLY
519
D2S69E
LAG-2
LAG2
NKG5
TLA519
granulysin [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GNLY mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 10578 GNLY
519
D2S69E
LAG-2
LAG2
NKG5
TLA519
granulysin pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GNLY mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 10578 GNLY
519
D2S69E
LAG-2
LAG2
NKG5
TLA519
granulysin [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of GNLY mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 3030 HADHA
ECHA
GBP
HADH
LCEH
LCHAD
MTPA
TP-ALPHA
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit (EC:4.2.1.17 1.1.1.211) [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HADHA mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 3030 HADHA
ECHA
GBP
HADH
LCEH
LCHAD
MTPA
TP-ALPHA
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), alpha subunit (EC:4.2.1.17 1.1.1.211) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HADHA mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 3035 HARS
HRS
USH3B
histidyl-tRNA synthetase (EC:6.1.1.21) pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HARS mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 3035 HARS
HRS
USH3B
histidyl-tRNA synthetase (EC:6.1.1.21) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HARS mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 3055 HCK
JTK9
p59Hck
p61Hck
hemopoietic cell kinase (EC:2.7.10.2) [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HCK mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 3055 HCK
JTK9
p59Hck
p61Hck
hemopoietic cell kinase (EC:2.7.10.2) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HCK mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 3074 HEXB
ENC-1AS
hexosaminidase B (beta polypeptide) (EC:3.2.1.52) Ionomycin results in increased secretion of HEXB protein increases secretion
protein 19758318
D015759 3146 HMGB1
HMG1
HMG3
SBP-1
high mobility group box 1 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HMGB1 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 3146 HMGB1
HMG1
HMG3
SBP-1
high mobility group box 1 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of HMGB1 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 3312 HSPA8
HSC54
HSC70
HSC71
HSP71
HSP73
HSPA10
LAP1
NIP71
heat shock 70kDa protein 8 bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA8 mRNA]] affects cotreatment
/ decreases reaction
/ increases expression
/ increases reaction
mRNA 15477007
D015759 3312 HSPA8
HSC54
HSC70
HSC71
HSP71
HSP73
HSPA10
LAP1
NIP71
heat shock 70kDa protein 8 pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of HSPA8 mRNA] affects cotreatment
/ increases expression
/ increases reaction
mRNA 15477007
D015759 3458 IFNG
IFG
IFI
interferon, gamma Aspirin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IFNG protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 15379866
D015759 3458 IFNG
IFG
IFI
interferon, gamma [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IFNG promoter affects cotreatment
/ increases activity
promoter 21569788
D015759 3458 IFNG
IFG
IFI
interferon, gamma [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IFNG protein affects cotreatment
/ increases secretion
protein 17685462
D015759 3458 IFNG
IFG
IFI
interferon, gamma nickel chloride inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IFNG promoter] affects cotreatment
/ decreases reaction
/ increases activity
promoter 21569788
D015759 3458 IFNG
IFG
IFI
interferon, gamma resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 16154495
D015759 3458 IFNG
IFG
IFI
interferon, gamma sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IFNG protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 17685462
D015759 3458 IFNG
IFG
IFI
interferon, gamma [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA affects cotreatment
/ increases expression
mRNA 12812920
D015759 3458 IFNG
IFG
IFI
interferon, gamma [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG protein affects cotreatment
/ increases expression
protein 12812920
15358692
16154495
17572062
D015759 3458 IFNG
IFG
IFI
interferon, gamma [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IFNG protein affects cotreatment
/ increases secretion
protein 15379866
D015759 3458 IFNG
IFG
IFI
interferon, gamma Zinc deficiency affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNG mRNA] affects cotreatment
/ affects reaction
/ increases expression
mRNA 12812920
D015759 3460 IFNGR2
AF-1
IFGR2
IFNGT1
interferon gamma receptor 2 (interferon gamma transducer 1) pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNGR2 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 3460 IFNGR2
AF-1
IFGR2
IFNGT1
interferon gamma receptor 2 (interferon gamma transducer 1) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IFNGR2 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 3586 IL10
CSIF
GVHDS
IL-10
IL10A
TGIF
interleukin 10 benzoquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 17572062
D015759 3586 IL10
CSIF
GVHDS
IL-10
IL10A
TGIF
interleukin 10 catechol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 17572062
D015759 3586 IL10
CSIF
GVHDS
IL-10
IL10A
TGIF
interleukin 10 hydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 17572062
D015759 3586 IL10
CSIF
GVHDS
IL-10
IL10A
TGIF
interleukin 10 hydroxyhydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 17572062
D015759 3586 IL10
CSIF
GVHDS
IL-10
IL10A
TGIF
interleukin 10 [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein affects cotreatment
/ increases secretion
protein 17685462
D015759 3586 IL10
CSIF
GVHDS
IL-10
IL10A
TGIF
interleukin 10 sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL10 protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 17685462
D015759 3586 IL10
CSIF
GVHDS
IL-10
IL10A
TGIF
interleukin 10 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL10 protein affects cotreatment
/ increases expression
protein 17572062
D015759 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL1B protein affects cotreatment
/ increases secretion
protein 17685462
D015759 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL1B protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 17685462
D015759 3553 IL1B
IL-1
IL1-BETA
IL1F2
interleukin 1, beta [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL1B protein affects cotreatment
/ increases expression
protein 17572062
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 1-Butanol inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased expression of IL2 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 18423386
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]] affects cotreatment
/ decreases reaction
/ increases secretion
protein 21075198
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 Aspirin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 15379866
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA]] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 Go 6976 inhibits the reaction [pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]] affects cotreatment
/ decreases reaction
/ increases expression
/ increases reaction
protein 16241859
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 promoter affects cotreatment
/ increases activity
promoter 21569788
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased expression of IL2 protein affects cotreatment
/ increases expression
protein 12165276
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein affects cotreatment
/ increases secretion
protein 17685462
21075198
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 Ionomycin results in increased expression of IL2 mRNA increases expression
mRNA 16055081
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 lenalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein] affects cotreatment
/ increases reaction
/ increases secretion
protein 16241859
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 nickel chloride inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased activity of IL2 promoter] affects cotreatment
/ decreases reaction
/ increases activity
promoter 21569788
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 21075198
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein] affects cotreatment
/ increases expression
/ increases reaction
protein 18423386
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA] affects cotreatment
/ increases expression
/ increases reaction
mRNA 16241859
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein] affects cotreatment
/ increases expression
/ increases reaction
protein 16241859
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein] affects cotreatment
/ increases reaction
/ increases secretion
protein 16241859
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 Pyrazoles analog inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 11592964
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 Pyrazoles analog inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 mRNA] affects cotreatment
/ decreases reaction
/ increases secretion
mRNA 11592964
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 16154495
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 rottlerin inhibits the reaction [pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein]] affects cotreatment
/ decreases reaction
/ increases expression
/ increases reaction
protein 16241859
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 SB 203580 inhibits the reaction [norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]] affects cotreatment
/ decreases reaction
/ increases secretion
protein 21075198
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 17685462
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 tert-Butyl Alcohol inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased expression of IL2 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 18423386
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA affects cotreatment
/ increases expression
mRNA 11592964
12812920
15477007
16241859
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein affects cotreatment
/ increases expression
protein 12812920
16154495
16241859
17572062
18423386
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 mRNA affects cotreatment
/ increases secretion
mRNA 11592964
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased secretion of IL2 protein affects cotreatment
/ increases secretion
protein 15379866
16241859
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 U 0126 inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased expression of IL2 protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 18423386
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 Zinc deficiency affects the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 mRNA] affects cotreatment
/ affects reaction
/ increases expression
mRNA 12812920
D015759 3558 IL2
IL-2
TCGF
lymphokine
interleukin 2 Zinc Sulfate inhibits the reaction [Ionomycin results in increased expression of IL2 mRNA] decreases reaction
/ increases expression
mRNA 16055081
D015759 3559 IL2RA
CD25
IDDM10
IL2R
TCGFR
interleukin 2 receptor, alpha Cyclosporine inhibits the reaction [Ionomycin results in increased secretion of IL2RA protein] decreases reaction
/ increases secretion
protein 8586487
D015759 3559 IL2RA
CD25
IDDM10
IL2R
TCGFR
interleukin 2 receptor, alpha [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2RA protein affects cotreatment
/ increases secretion
protein 8586487
D015759 3559 IL2RA
CD25
IDDM10
IL2R
TCGFR
interleukin 2 receptor, alpha Ionomycin results in increased secretion of IL2RA protein increases secretion
protein 8586487
D015759 3559 IL2RA
CD25
IDDM10
IL2R
TCGFR
interleukin 2 receptor, alpha Sirolimus inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2RA protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 8586487
D015759 3559 IL2RA
CD25
IDDM10
IL2R
TCGFR
interleukin 2 receptor, alpha Sirolimus inhibits the reaction [Ionomycin results in increased secretion of IL2RA protein] decreases reaction
/ increases secretion
protein 8586487
D015759 3560 IL2RB
CD122
IL15RB
P70-75
interleukin 2 receptor, beta [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RB mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 3560 IL2RB
CD122
IL15RB
P70-75
interleukin 2 receptor, beta pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RB mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 3560 IL2RB
CD122
IL15RB
P70-75
interleukin 2 receptor, beta [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2RB mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 3565 IL4
BCGF-1
BCGF1
BSF-1
BSF1
IL-4
interleukin 4 [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL4 protein affects cotreatment
/ increases secretion
protein 17685462
D015759 3565 IL4
BCGF-1
BCGF1
BSF-1
BSF1
IL-4
interleukin 4 sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL4 protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 17685462
D015759 3565 IL4
BCGF-1
BCGF1
BSF-1
BSF1
IL-4
interleukin 4 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL4 protein affects cotreatment
/ increases expression
protein 17572062
D015759 3567 IL5
EDF
IL-5
TRF
interleukin 5 (colony-stimulating factor, eosinophil) [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL5 protein affects cotreatment
/ increases secretion
protein 17685462
D015759 3567 IL5
EDF
IL-5
TRF
interleukin 5 (colony-stimulating factor, eosinophil) sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL5 protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 17685462
D015759 3567 IL5
EDF
IL-5
TRF
interleukin 5 (colony-stimulating factor, eosinophil) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL5 protein affects cotreatment
/ increases expression
protein 17572062
D015759 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) [Ionomycin co-treated with Lipopolysaccharides] results in increased expression of IL6 protein affects cotreatment
/ increases expression
protein 20682585
D015759 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein affects cotreatment
/ increases secretion
protein 17685462
D015759 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) Ionomycin promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] increases expression
/ increases reaction
mRNA 20682585
D015759 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) Ionomycin results in increased expression of IL6 mRNA increases expression
mRNA 20682585
D015759 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL6 protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 17685462
D015759 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL6 mRNA affects cotreatment
/ increases expression
mRNA 18434080
D015759 3569 IL6
BSF2
HGF
HSF
IFNB2
IL-6
interleukin 6 (interferon, beta 2) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL6 protein affects cotreatment
/ increases expression
protein 17572062
D015759 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL8 protein affects cotreatment
/ increases secretion
protein 17685462
21075198
D015759 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Ionomycin inhibits the reaction [3-amino-1,4-dimethyl-5H-pyrido(4,3-b)indole inhibits the reaction [Lipopolysaccharides results in increased expression of IL8 protein]] decreases reaction
/ increases expression
protein 18281166
D015759 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 Ionomycin promotes the reaction [Neurotensin results in increased expression of IL8 mRNA] increases expression
/ increases reaction
mRNA 17000667
D015759 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL8 protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 17685462
D015759 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL8 mRNA affects cotreatment
/ increases expression
mRNA 18434080
D015759 3576 IL8
CXCL8
GCP-1
GCP1
LECT
LUCT
LYNAP
MDNCF
MONAP
NAF
NAP-1
NAP1
interleukin 8 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL8 protein affects cotreatment
/ increases expression
protein 17572062
D015759 3662 IRF4
LSIRF
MUM1
NF-EM5
interferon regulatory factor 4 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IRF4 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 3662 IRF4
LSIRF
MUM1
NF-EM5
interferon regulatory factor 4 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IRF4 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein]] affects cotreatment
/ decreases reaction
/ increases expression
/ increases reaction
protein 15477007
D015759 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene Capsaicin inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 9580328
D015759 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene Methohexital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15263067
D015759 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene Pentobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15263067
D015759 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein] affects cotreatment
/ increases expression
/ increases reaction
protein 15477007
D015759 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene Secobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15263067
D015759 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which binds to DPYD promoter] affects binding
/ affects cotreatment
/ increases reaction
protein 15705907
D015759 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene [Tetradecanoylphorbol Acetate co-treated with Ionomycin] promotes the reaction [[FOS protein binds to JUN protein] which results in increased expression of DPYD mRNA] affects binding
/ affects cotreatment
/ increases expression
/ increases reaction
protein 15705907
D015759 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA affects cotreatment
/ increases expression
mRNA 15263067
D015759 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN protein affects cotreatment
/ increases expression
protein 9580328
15477007
D015759 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene Thiamylal inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15263067
D015759 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene Thiopental inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of JUN mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15263067
D015759 3783 KCNN4
IK1
IKCA1
KCA4
KCa3.1
SK4
hIKCa1
hKCa4
hSK4
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 Clotrimazole inhibits the reaction [[Ionomycin co-treated with Tetraethylammonium] results in increased activity of KCNN4 protein] affects cotreatment
/ decreases reaction
/ increases activity
protein 14985237
D015759 3783 KCNN4
IK1
IKCA1
KCA4
KCa3.1
SK4
hIKCa1
hKCa4
hSK4
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 [Ionomycin co-treated with Tetraethylammonium] results in increased activity of KCNN4 protein affects cotreatment
/ increases activity
protein 14985237
D015759 9314 KLF4
EZF
GKLF
Kruppel-like factor 4 (gut) pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of KLF4 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 9314 KLF4
EZF
GKLF
Kruppel-like factor 4 (gut) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of KLF4 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 1316 KLF6
BCD1
CBA1
COPEB
CPBP
GBF
PAC1
ST12
ZF9
Kruppel-like factor 6 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of KLF6 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 1316 KLF6
BCD1
CBA1
COPEB
CPBP
GBF
PAC1
ST12
ZF9
Kruppel-like factor 6 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of KLF6 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 3845 KRAS
C-K-RAS
CFC2
K-RAS2A
K-RAS2B
K-RAS4A
K-RAS4B
KI-RAS
KRAS1
KRAS2
NS
NS3
RASK2
Kirsten rat sarcoma viral oncogene homolog Methohexital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein] affects cotreatment
/ decreases reaction
/ increases activity
protein 15263067
D015759 3845 KRAS
C-K-RAS
CFC2
K-RAS2A
K-RAS2B
K-RAS4A
K-RAS4B
KI-RAS
KRAS1
KRAS2
NS
NS3
RASK2
Kirsten rat sarcoma viral oncogene homolog Pentobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein] affects cotreatment
/ decreases reaction
/ increases activity
protein 15263067
D015759 3845 KRAS
C-K-RAS
CFC2
K-RAS2A
K-RAS2B
K-RAS4A
K-RAS4B
KI-RAS
KRAS1
KRAS2
NS
NS3
RASK2
Kirsten rat sarcoma viral oncogene homolog Secobarbital inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein] affects cotreatment
/ decreases reaction
/ increases activity
protein 15263067
D015759 3845 KRAS
C-K-RAS
CFC2
K-RAS2A
K-RAS2B
K-RAS4A
K-RAS4B
KI-RAS
KRAS1
KRAS2
NS
NS3
RASK2
Kirsten rat sarcoma viral oncogene homolog Thiamylal inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of KRAS protein] affects cotreatment
/ decreases reaction
/ increases activity
protein 15263067
D015759 3936 LCP1
CP64
L-PLASTIN
LC64P
LPL
PLS2
lymphocyte cytosolic protein 1 (L-plastin) [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of LCP1 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 3936 LCP1
CP64
L-PLASTIN
LC64P
LPL
PLS2
lymphocyte cytosolic protein 1 (L-plastin) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of LCP1 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 8425 LTBP4
ARCL1C
LTBP-4
LTBP4L
LTBP4S
latent transforming growth factor beta binding protein 4 [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LTBP4 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 8425 LTBP4
ARCL1C
LTBP-4
LTBP4L
LTBP4S
latent transforming growth factor beta binding protein 4 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LTBP4 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 8425 LTBP4
ARCL1C
LTBP-4
LTBP4L
LTBP4S
latent transforming growth factor beta binding protein 4 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of LTBP4 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 5605 MAP2K2
CFC4
MAPKK2
MEK2
MKK2
PRKMK2
mitogen-activated protein kinase kinase 2 (EC:2.7.12.2) pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of MAP2K2 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 5605 MAP2K2
CFC4
MAPKK2
MEK2
MKK2
PRKMK2
mitogen-activated protein kinase kinase 2 (EC:2.7.12.2) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of MAP2K2 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) 1-Butanol inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein] affects cotreatment
/ decreases reaction
/ increases activity
/ increases phosphorylation
protein 18423386
D015759 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK1 protein]] affects cotreatment
/ decreases reaction
/ increases phosphorylation
/ increases reaction
protein 15477007
D015759 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) [Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK1 protein affects cotreatment
/ increases phosphorylation
protein 22317921
D015759 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein] affects cotreatment
/ increases activity
/ increases phosphorylation
/ increases reaction
protein 18423386
D015759 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK1 protein] affects cotreatment
/ increases phosphorylation
/ increases reaction
protein 15477007
D015759 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein affects cotreatment
/ increases activity
/ increases phosphorylation
protein 18423386
D015759 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK1 protein affects cotreatment
/ increases phosphorylation
protein 15477007
D015759 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK3 protein]] affects cotreatment
/ decreases reaction
/ increases phosphorylation
/ increases reaction
protein 15477007
D015759 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) [Ionomycin co-treated with EGF protein] results in increased phosphorylation of MAPK3 protein affects cotreatment
/ increases phosphorylation
protein 22317921
D015759 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein] affects cotreatment
/ increases activity
/ increases phosphorylation
/ increases reaction
protein 18423386
D015759 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) pyrrolidine dithiocarbamic acid promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK3 protein] affects cotreatment
/ increases phosphorylation
/ increases reaction
protein 15477007
D015759 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein affects cotreatment
/ increases activity
/ increases phosphorylation
protein 18423386
D015759 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of MAPK3 protein affects cotreatment
/ increases phosphorylation
protein 15477007
D015759 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) U 0126 inhibits the reaction [[4-O-methyl-12-O-tetradecanoylphorbol 13-acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein] affects cotreatment
/ decreases reaction
/ increases activity
/ increases phosphorylation
protein 18423386
D015759 4609 MYC
MRTL
MYCC
bHLHe39
c-Myc
v-myc avian myelocytomatosis viral oncogene homolog [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MYC mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 4609 MYC
MRTL
MYCC
bHLHe39
c-Myc
v-myc avian myelocytomatosis viral oncogene homolog pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MYC mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 4609 MYC
MRTL
MYCC
bHLHe39
c-Myc
v-myc avian myelocytomatosis viral oncogene homolog [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of MYC mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 24142 NAT6
FUS-2
FUS2
N-acetyltransferase 6 (GCN5-related) (EC:2.3.1.-) [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NAT6 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 24142 NAT6
FUS-2
FUS2
N-acetyltransferase 6 (GCN5-related) (EC:2.3.1.-) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NAT6 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 4745 NELL1
IDH3GL
NRP1
NEL-like 1 (chicken) [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NELL1 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 4745 NELL1
IDH3GL
NRP1
NEL-like 1 (chicken) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NELL1 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 4792 NFKBIA
IKBA
MAD-3
NFKBI
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased degradation of NFKBIA protein] affects cotreatment
/ decreases reaction
/ increases degradation
protein 15477007
D015759 4792 NFKBIA
IKBA
MAD-3
NFKBI
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased degradation of NFKBIA protein affects cotreatment
/ increases degradation
protein 15477007
D015759 4818 NKG7
GIG1
GMP-17
p15-TIA-1
natural killer cell group 7 sequence pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NKG7 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 4818 NKG7
GIG1
GMP-17
p15-TIA-1
natural killer cell group 7 sequence [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NKG7 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 9111 NMI
N-myc (and STAT) interactor [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NMI mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 9111 NMI
N-myc (and STAT) interactor [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NMI mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 4854 NOTCH3
CADASIL
CASIL
IMF2
notch 3 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NOTCH3 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 4854 NOTCH3
CADASIL
CASIL
IMF2
notch 3 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of NOTCH3 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 8013 NR4A3
CHN
CSMF
MINOR
NOR1
TEC
nuclear receptor subfamily 4, group A, member 3 [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NR4A3 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 8013 NR4A3
CHN
CSMF
MINOR
NOR1
TEC
nuclear receptor subfamily 4, group A, member 3 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of NR4A3 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 5338 PLD2
phospholipase D2 (EC:3.1.4.4) PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of IL2 protein] affects cotreatment
/ increases expression
/ increases reaction
protein 18423386
D015759 5338 PLD2
phospholipase D2 (EC:3.1.4.4) PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK1 protein] affects cotreatment
/ increases activity
/ increases phosphorylation
/ increases reaction
protein 18423386
D015759 5338 PLD2
phospholipase D2 (EC:3.1.4.4) PLD2 protein promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased phosphorylation of and results in increased activity of MAPK3 protein] affects cotreatment
/ increases activity
/ increases phosphorylation
/ increases reaction
protein 18423386
D015759 8228 PNPLA4
DXS1283E
GS2
iPLA2eta
patatin-like phospholipase domain containing 4 (EC:3.1.1.3) pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of PNPLA4 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 8228 PNPLA4
DXS1283E
GS2
iPLA2eta
patatin-like phospholipase domain containing 4 (EC:3.1.1.3) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of PNPLA4 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 5451 POU2F1
OCT1
OTF1
oct-1B
POU class 2 homeobox 1 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of POU2F1 protein affects cotreatment
/ increases activity
protein 16241859
D015759 5452 POU2F2
OCT2
OTF2
Oct-2
POU class 2 homeobox 2 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of POU2F2 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 5452 POU2F2
OCT2
OTF2
Oct-2
POU class 2 homeobox 2 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of POU2F2 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 5588 PRKCQ
PRKCT
nPKC-theta
protein kinase C, theta (EC:2.7.11.13) pomalidomide promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of PRKCQ protein] affects cotreatment
/ increases activity
/ increases reaction
protein 16241859
D015759 5588 PRKCQ
PRKCT
nPKC-theta
protein kinase C, theta (EC:2.7.11.13) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased activity of PRKCQ protein affects cotreatment
/ increases activity
protein 16241859
D015759 1827 RCAN1
ADAPT78
CSP1
DSC1
DSCR1
MCIP1
RCN1
regulator of calcineurin 1 Ionomycin results in increased expression of RCAN1 protein increases expression
protein 12927602
D015759 5966 REL
C-Rel
v-rel avian reticuloendotheliosis viral oncogene homolog [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of REL mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 5966 REL
C-Rel
v-rel avian reticuloendotheliosis viral oncogene homolog pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of REL mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 5966 REL
C-Rel
v-rel avian reticuloendotheliosis viral oncogene homolog [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of REL mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 391 RHOG
ARHG
ras homolog family member G pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of RHOG mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 391 RHOG
ARHG
ras homolog family member G [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of RHOG mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 8635 RNASET2
RNASE6PL
bA514O12.3
ribonuclease T2 (EC:3.1.27.1) pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of RNASET2 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 8635 RNASET2
RNASE6PL
bA514O12.3
ribonuclease T2 (EC:3.1.27.1) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of RNASET2 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 9092 SART1
Ara1
HOMS1
SART1259
SNRNP110
Snu66
squamous cell carcinoma antigen recognized by T cells pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SART1 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 9092 SART1
Ara1
HOMS1
SART1259
SNRNP110
Snu66
squamous cell carcinoma antigen recognized by T cells [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SART1 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 10262 SF3B4
AFD1
Hsh49
SAP49
SF3b49
splicing factor 3b, subunit 4, 49kDa pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SF3B4 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 10262 SF3B4
AFD1
Hsh49
SAP49
SF3b49
splicing factor 3b, subunit 4, 49kDa [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of SF3B4 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 6503 SLA
SLA1
SLAP
Src-like-adaptor [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLA mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 6503 SLA
SLA1
SLAP
Src-like-adaptor pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLA mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 6503 SLA
SLA1
SLAP
Src-like-adaptor [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLA mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 7922 SLC39A7
D6S115E
D6S2244E
H2-KE4
HKE4
KE4
RING5
ZIP7
solute carrier family 39 (zinc transporter), member 7 Ionomycin promotes the reaction [EGF protein promotes the reaction [CSNK2A1 protein binds to SLC39A7 protein]] affects binding
/ increases reaction
protein 22317921
D015759 6520 SLC3A2
4F2
4F2HC
4T2HC
CD98
CD98HC
MDU1
NACAE
solute carrier family 3 (amino acid transporter heavy chain), member 2 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLC3A2 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 6520 SLC3A2
4F2
4F2HC
4T2HC
CD98
CD98HC
MDU1
NACAE
solute carrier family 3 (amino acid transporter heavy chain), member 2 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SLC3A2 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 6648 SOD2
IPOB
MNSOD
MVCD6
superoxide dismutase 2, mitochondrial (EC:1.15.1.1) SOD2 protein results in decreased susceptibility to [Tetradecanoylphorbol Acetate co-treated with Ionomycin] affects cotreatment
/ decreases response to substance
protein 22429591
D015759 6734 SRPR
DP
Sralpha
signal recognition particle receptor (docking protein) [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SRPR mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 6734 SRPR
DP
Sralpha
signal recognition particle receptor (docking protein) [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of SRPR mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 6786 STIM1
D11S4896E
GOK
IMD10
TAM
stromal interaction molecule 1 [Thapsigargin co-treated with Ionomycin] promotes the reaction [STIM1 protein binds to ATP2A3 protein] affects binding
/ affects cotreatment
/ increases reaction
protein 18439569
D015759 7040 TGFB1
CED
DPD1
LAP
TGFB
TGFbeta
transforming growth factor, beta 1 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TGFB1 mRNA affects cotreatment
/ increases expression
mRNA 18434080
D015759 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor hydroquinone inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 10890505
D015759 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor [Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein affects cotreatment
/ increases secretion
protein 17685462
21075198
D015759 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor Ionomycin inhibits the reaction [[N-(4-hydroxyphenyl)arachidonylamide co-treated with Tetradecanoylphorbol Acetate] results in increased expression of TNF protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 17196940
D015759 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor resveratrol inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein] affects cotreatment
/ decreases reaction
/ increases expression
protein 16154495
D015759 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor sodium bichromate inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of TNF protein] affects cotreatment
/ decreases reaction
/ increases secretion
protein 17685462
D015759 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF mRNA affects cotreatment
/ increases expression
mRNA 18434080
D015759 7124 TNF
DIF
TNF-alpha
TNFA
TNFSF2
tumor necrosis factor [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TNF protein affects cotreatment
/ increases expression
protein 10890505
15358692
16154495
17572062
D015759 7133 TNFRSF1B
CD120b
TBPII
TNF-R-II
TNF-R75
TNFBR
TNFR1B
TNFR2
TNFR80
p75
p75TNFR
tumor necrosis factor receptor superfamily, member 1B [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TNFRSF1B mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 7133 TNFRSF1B
CD120b
TBPII
TNF-R-II
TNF-R75
TNFBR
TNFR1B
TNFR2
TNFR80
p75
p75TNFR
tumor necrosis factor receptor superfamily, member 1B [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TNFRSF1B mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 8744 TNFSF9
4-1BB-L
CD137L
tumor necrosis factor (ligand) superfamily, member 9 [Ionomycin co-treated with Phorbol Esters] promotes the reaction [entinostat results in increased expression of TNFSF9 mRNA] affects cotreatment
/ increases expression
/ increases reaction
mRNA 19759901
D015759 8744 TNFSF9
4-1BB-L
CD137L
tumor necrosis factor (ligand) superfamily, member 9 [Ionomycin co-treated with Phorbol Esters] promotes the reaction [trichostatin A results in increased expression of TNFSF9 mRNA] affects cotreatment
/ increases expression
/ increases reaction
mRNA 19759901
D015759 8744 TNFSF9
4-1BB-L
CD137L
tumor necrosis factor (ligand) superfamily, member 9 [Ionomycin co-treated with Phorbol Esters] promotes the reaction [vorinostat results in increased expression of TNFSF9 mRNA] affects cotreatment
/ increases expression
/ increases reaction
mRNA 19759901
D015759 7185 TRAF1
EBI6
MGC:10353
TNF receptor-associated factor 1 [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 7185 TRAF1
EBI6
MGC:10353
TNF receptor-associated factor 1 bathocuproine sulfonate inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA]] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 7185 TRAF1
EBI6
MGC:10353
TNF receptor-associated factor 1 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 7185 TRAF1
EBI6
MGC:10353
TNF receptor-associated factor 1 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of TRAF1 mRNA affects cotreatment
/ increases expression
mRNA 15477007
D015759 28951 TRIB2
C5FW
GS3955
TRB2
tribbles pseudokinase 2 pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TRIB2 mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 28951 TRIB2
C5FW
GS3955
TRB2
tribbles pseudokinase 2 [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TRIB2 mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 7442 TRPV1
VR1
transient receptor potential cation channel, subfamily V, member 1 Ionomycin results in increased activity of TRPV1 protein increases activity
protein 11606325
D015759 7305 TYROBP
DAP12
KARAP
PLOSL
TYRO protein tyrosine kinase binding protein [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TYROBP mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 7305 TYROBP
DAP12
KARAP
PLOSL
TYRO protein tyrosine kinase binding protein pyrrolidine dithiocarbamic acid inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TYROBP mRNA] affects cotreatment
/ decreases expression
/ decreases reaction
mRNA 15477007
D015759 7305 TYROBP
DAP12
KARAP
PLOSL
TYRO protein tyrosine kinase binding protein [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of TYROBP mRNA affects cotreatment
/ decreases expression
mRNA 15477007
D015759 7431 VIM
CTRCT30
vimentin [bathocuproine sulfonate co-treated with pyrrolidine dithiocarbamic acid] inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of VIM mRNA] affects cotreatment
/ decreases reaction
/ increases expression
mRNA 15477007
D015759 7431 VIM
CTRCT30
vimentin [Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in increased expression of VIM mRNA affects cotreatment
/ increases expression
mRNA 15477007

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (6)

OMIM preferred title UniProt
#600274 Frontotemporal dementia; ftd P10636
#607948 Mycobacterium tuberculosis, susceptibility to P11473
#260540 Parkinson-dementia syndrome P10636
#172700 Pick disease of brain P10636
#601104 Supranuclear palsy, progressive, 1; psnp1 P10636
#277440 Vitamin d-dependent rickets, type 2a; vddr2a P11473

KEGG DISEASE (6)

KEGG disease name UniProt
H00058 Amyotrophic lateral sclerosis (ALS) P10636 (related)
H00077 Progressive supranuclear palsy (PSP) P10636 (related)
H00078 Frontotemporal lobar degeneration (FTLD) P10636 (related)
H00342 Tuberculosis P11473 (related)
H00784 Localized autosomal recessive hypotrichosis P11473 (related)
H01143 Vitamin D-dependent rickets P11473 (related)